Abiopharma

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026

GRI Bio Announces Reverse Stock Split

Incoming CEO Paul Bloom and Long-Time Leader Patrick Gruber to Participate in Virtual Fireside Chat

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

Arcellx - Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Jushi Holdings Inc. Announces Grand Opening of Second Beyond Hello™ in Cincinnati, Ohio, Expanding its Statewide Retail Footprint

New Form SCHEDULE 13G/A - Cogent Biosciences, Inc. Filed: 2026-01-21 AccNo: 0002012383-26-000802 Size: 11 KB

Director ANGEL STEPHEN F 🟡 adjusted position in 1.0M shares (14 derivative) of LINDE PLC (LIN) at $440.04 ($153.7M) Transaction Date: Jan 20, 2026 | Filing ID: 000002

agilon health, inc. (AGL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Jin Medical International Ltd. Management Plans For Fireside Chat

New Form SCHEDULE 13G/A - Biophytis SA Filed: 2026-01-21 AccNo: 0002052113-26-000214 Size: 10 KB

Quest Diagnostics Named to Fortunes Worlds Most Admired Companies List for 12th Consecutive Year